Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - rosuvastatin calcium - filmovertrukne tabletter - 40 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - rosuvastatin calcium - filmovertrukne tabletter - 5 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - telmisartan - filmovertrukne tabletter - 40 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - telmisartan - filmovertrukne tabletter - 80 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - cinacalcethydrochlorid - filmovertrukne tabletter - 30 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - cinacalcethydrochlorid - filmovertrukne tabletter - 60 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - cinacalcethydrochlorid - filmovertrukne tabletter - 90 mg

Euroopa Liit - taani - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Euroopa Liit - taani - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiske - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).